(12) United States Patent
`(10) Patent N0.:
`US 8,741,929 B2
`Zeldis
`(45) Date of Patent:
`*Jun. 3, 2014
`
`USOO8741929B2
`
`(54)
`
`METHODS USING 3-(4-AMINO-1-OXO-1,3-
`DIHYDRO-ISOINDOL-Z-YL)—PIPERIDINE-
`2,6-DIONE FOR TREATMENT OF MANTLE
`CELL LYMPHOlVIAS
`
`(75)
`
`Inventor:
`
`Jerome B. Zeldis, Princeton, NJ (US)
`
`(73)
`
`Assignee:
`
`(Ielgene Corporation, Summit, NJ (US)
`
`(*)
`
`Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 220 days.
`
`This patent is subject to a terminal dis-
`claimer.
`
`(21)
`
`Appl. No.2 12/621,502
`
`(22)
`
`(65)
`
`(63)
`
`(60)
`
`(51)
`
`(52)
`
`(58)
`
`(56)
`
`Filed:
`
`Nov. 19, 2009
`
`Prior Publication Data
`
`US 2010/0068206 A1
`
`Mar. 18, 2010
`
`Related U.S. Application Data
`
`Continuation of application No. 11/888,881, filed on
`Aug. 1, 2007, now abandoned.
`
`Provisional application No. 60/835,752, filed on Aug.
`3, 2006.
`
`(2006.01)
`
`Int. Cl.
`A61K 31/445
`U.S. Cl.
`USPC .......................................................... 514/323
`Field of Classification Search
`None
`See application file for complete search history.
`References Cited
`
`5,733,566 A
`5,798,368 A
`5,874,448 A
`5,877,200 A
`5,929,117 A
`5,955,476 A
`6,020,358 A
`6,071,948 A
`6,114,355 A
`6,140,346 A
`6,228,879 B
`6,235,756 B
`6,281,230 B
`6,316,471 B
`6,326,388 B
`6,335,349 B
`6,380,239 13
`6,395,754 B
`6,403,613 B
`6,420,414 B
`6,458,810 B
`6,469,045 B
`6,476,052 B
`6,518,298 B2
`6,555,554 B2
`6,673,828 B
`7,468,363 B2
`2001/0018445 A
`2001/0056114 A
`2002/0035090 A
`2002/0045643 A
`
`
`
`3/1998 Lewis
`8/1998 Muller etal.
`2/1999 Muller et al.
`3/1999 Muller
`7/1999 Muller et al.
`9/1999 Muller et al.
`2/2000 Muller ct al.
`6/2000 D’Amato
`9/2000 D’Amato
`10/2000 Andrulis, Jr. et al.
`5/2001 Green et al.
`5/2001 D’Amato
`8/2001 Muller et al.
`11/2001 Muller et al.
`12/2001 Man ct al.
`1/2002 Muller et al.
`4/2002 Muller et al.
`5/2002 Muller et al.
`6/2002 Man et al.
`7/2002 D’Amato
`10/2002 Muller et al.
`10/2002 D’Amato
`11/2002 Muller et al.
`2/2003 Green et a1.
`4/2003 Muller et al.
`1/2004 Green et al.
`12/2008 Zeldis
`8/2001 Huang et al.
`12/2001 D’Amato
`3/2002 Zeldis et al.
`4/2002 Muller et al.
`
`(Continued)
`
`FOREIGN PATle DOCUMENTS
`
`
`2006-514689
`JP
`WO 98/03502
`W0
`WO 98/54170
`W0
`WO 01/70275
`W0
`WO 01/87307
`W0
`W0 02/059106
`W0
`W0 02/064083
`W0
`PCT/US03/11578
`WO
`W003086373
`WO
`W0 03/097052
`W0
`W0 W0 2004/043 377
`
`5/2006
`1/1998
`12/1998
`/2001
`11/2001
`8/2002
`[’2002
`10/2003
`10/2003
`11/2003
`5/2004
`
`U.S. PATENT DOCUMENTS
`
`OTHER PUBLICATIONS
`
`3,536,809 A
`3,598,123 A
`3,845,770 A
`3,916,899 A
`4,008,719 A
`4,810,643 A
`4,999,291 A
`5,059,595 A
`5,073,543 A
`5,120,548 A
`5,134,127 A
`5,229,496 A
`5,354,556 A
`5,385,901 A
`5,391,485 A
`5,393,870 A
`5,528,823 A
`5,580,755 A
`5,591,767 A
`5,593,990 A
`5,629,327 A
`5,635,517 A
`5,639,476 A
`5,674,533 A
`5,698,579 A
`5,712,291 A
`5,731,325 A
`
`10/1970 Applezweig
`8/1971 Zaffaroni et a1.
`11/1974 Theeuwes et al.
`11/1975 Theeuwes et al.
`2/1977 Theeuwes et al.
`3/1989 Souza
`3/1991 Souza
`10/1991
`I.e Grazie
`12/1991 Marshall et al.
`6/1992 McClelland et al.
`7/1992 Stella et al.
`7/1993 Deeley et al.
`10/1994 Sparks et 31.
`1/1995 Kaplan et al.
`2/1995 Deelcy ct a1.
`2/1995 Deeley et al.
`6/1996 Rudy, Jr et al.
`12/1996 Souza
`1/1997 Mohr et a1.
`1/1997 D’Amato
`5/1997 D‘Amato
`6/1997 Muller et 31.
`6/1997 Oshlack ct al.
`10/1997 Santus et al.
`12/1997 Muller
`1/1998 D’Amato
`3/1998 Andrulis, Jr. et al.
`
`Translation of the Official Action from Russian Patent Office, May
`31, 2011.
`Bartlett et al., “Recent clinical studies of the immunornodulatory
`drug (IMiD) lenalidomide”, British Journal of Cancer, 2005, 93,
`613-619.
`
`(Continued)
`
`Primary Examiner 7 James D Anderson
`(74) Attorney, Agent, or Firm 7 Jones Day
`
`ABSTRACT
`(57)
`Methods oftreating, preventing or managing mantle cell lym—
`phomas are disclosed. The methods encompass the adininis—
`tration of an inununornodulatory compound of the invention
`known as Revlimid® or lenalidomide. The invention further
`relates to methods of treatment using this compound with
`chemotherapy, radiation therapy, hormonal therapy, biologi—
`cal therapy or iinmunotherapy. Pharmaceutical compositions
`and single tmit dosage forms suitable for use in the methods of
`the invention are also disclosed.
`
`24 Claims, No Drawings
`
`Apotex EX. 1001, p. 1
`
`Apotex Ex. 1001, p. 1
`
`

`

`US 8,741,929 B2
`
`Page 2
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`2002/0052398 A1
`2002/0054899 A1
`2002/0061923 A1
`2002/0128228 A1
`2002/0161023 A1
`2002/0173658 A1
`2002/0183360 A1
`2003/0013739 A1
`2003/0028028 A1
`2003/0045552 A1
`2003/0069428 A1
`2003/0096841 A1
`2003/0139451 A1
`2003/0144325 A1
`2003/0181428 A1
`2003/0187024 A1
`2003/0191098 A1
`2003/0235909 A1
`2004/0029832 A1
`2004/0077685 A1
`2004/0077686 A1
`2004/0087546 A1
`2004/0091455 A1
`2004/0122052 A1
`2004/0266809 A1
`2010/0196369 A1
`
`5/2002 D’Amato
`5/2002 Zeldis
`5/2002 D’Amato
`9/2002 ku
`10/2002 D’Amato
`l 1/2002 Muller et al.
`12/2002 Muller et al.
`1/2003 Masferrer et al.
`2/2003 Man et a1.
`3/2003 Robarge et al.
`4/2003 Muller et al.
`5/2003 Robarge et a1.
`7/2003 Shah et al.
`7/2003 Muller et al.
`9/2003 Green et al.
`10/2003 D’Amato
`10/2003 D’Amato
`12/2003 Hariri et al.
`2/2004 Zeldis
`4/2004 Figg et a1.
`4/2004 Dannenberg et a1.
`5/2004 Zeldis
`5/2004 7.eldis
`6/2004 Muller et al.
`12/2004 Emanuel et al.
`8/2010 Zeldis
`
`
`
`OTHER PUBLICATIONS
`
`Thomas E. W'itzig, “Current Treatment Approaches for Mantle-Cell
`Lymphoma”. Journal ofCinical Oncology. 2005. 23. 26. 6409-6414.
`Carstensen, 1995, Drug Stability: Principles & Practice, 2”“ cd.,
`Marcel Dckkcr, New York. NY pp. 379-380.
`Corral et al., 1999. “Immunomodulation by thalidomide and
`thalidomide analogues," Ann. Rheum. Dis. 58(Suppl l):IlO7—113.
`Craig
`et
`al.,
`1967,
`“Potential
`anticancer
`agents.
`III.
`2-phthalimidoa1dehydes and derivatives,” Potential Anticancer
`Agents 111 10:1071—1073.
`Crane, et al.. “Immunomodulatory Drugs,” Cancer Investigation,
`2005, 23:625-634.
`Cunningham et al., “Phase II Trial for Lcnalidomide Alone in
`Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma.” Clini—
`cal Lymphoma &Myel0ma, 2007. 7(5):339.
`D’Amato et al., 2001, “Mechanism of action of thalidomide and
`3-aminothalidomide in multiple myeloma,” Semin Oncol. 28:59"-
`601.
`D’Amato et al , 1994, “Thalidomide is an Inhibitor ofAngiogenesis”,
`Proc. Natl. Acad. Sci. 91:4082-4085.
`some antineoplastic
`for
`De et al.,
`1976, “IIansch analysis
`glutarimides,” J. Indian Chem. Soc. I:III: 825-826.
`De et al., 1976, “Possible antineoplastic agents: 111. Synthesis of
`6 -alkyl-2 -[4'-methoxyphthalimido]
`and
`6-alkyl-3 - [3’ -4' -
`dimethoxyphenyl] glutarimides.” J. Indian Chem. Soc. I.III:1122-
`l 125.
`Dredge et al.. 2002, “Novel thalidomide analogues display anti-
`angiogenic activity independently of immunomodulatory effects.”
`Br. J. Cancer 87(10):1166-1172.
`Folkman et al.. 1983. “Angiogenesis inhibition and tumor regression
`caused byheparin or aheparin fragment in thepresence ofcortisone.”
`Science 221(4612):719-725.
`Gershbein, 1991, “The thalidomide analog. EM 12, enhances 1,2-
`dimethylhydrazine-induction of rat colon adenocarcinomas.” Cancer
`Letters 60: 129-133.
`Grabstald et al., 1965, “Clinical experiences with thalidomide in
`patients with cancer,” Clinical Pharmacology and Therapeutics
`6:298-302.
`Lentzsch et al., 2003, “Immunomodulatory analogs of thalidomide
`inhibit growth ofHs Sultan cells and angiogenesis in vivo.” Leukemia
`l7(l):4l-44.
`Lentzsch et al.. 2002, “S-3-amino-phthalimido-glutarimide inhibits
`angiogenesis and growth of B-cell neoplasias in mice”, Cancer
`Research 62:2300-2305.
`
`response modifiers:
`1997, “Novel biological
`Miyachi et al.,
`phthalimides with tumor necrosis factor-alpha production-regulating
`activity,” J. Med. Chem. 40:2858-2865.
`Muller et al., 1999. “Amino-substituted thalidomide analogs: potent
`inhibitors of TNF-alpha production," Bioorg. Med. Chem. Lett.
`9(1 01625-1630.
`Muller et al.. 1998. "Thalidomide analogs and PDE4 inhibition.”
`Bioorg. Med. Chem. Lett. 8(19):2669-2674.
`Muller et al., 1996, “Structural modifications ofthalidomide produce
`analogs with enhanced tumor necrosis factor inhibitory activity,” J.
`Med. Chem. 39(17):323R-3240.
`Olson et al., 1965. “Thalidomide (N-phthaloylglutamimide) in the
`treatment of advanced cancer.” Clinical Pharmacology and Thera-
`peutics 6(3):292—297.
`Penichet et al., 2001, “Antibody-cytokine fusion proteins for the
`therapy of cancer,” J. Immunol. Methods 248(1-2):9l-101.
`Physician’s Desk Reference, 2002, 56’” ed., pp. 1755—1760.
`Raza et al., 2001. “Thalidomide produces transfusion independence
`in long-standing refractory anemias of patients with myelodysplatic
`syndromes,” Blood 98(4):958-965.
`Shah et al.. 1999. “Synthesis and enantiomeric separation of
`2-phthalimidinc-glutaric acid analogues: potent inhibitors of tumor
`metastasis,” J. Med. Chem. 42:3014-3017.
`Shibata et al., 1995, “N -alky1phthalimides: structural requirement of
`thalidomidal action on l2-0-tetradecanoylphorbol-l3-acetate-in-
`duced tumor necrosis factor a production by human leukemia HL—60
`cells,” Chem. Pharm. Bull. 43(1):177-179.
`Shimazawa et al., 1999. “Antiangiogenic activity of tumor necrosis
`factor-alpha production regulators derived from thalidomide,” Biol.
`Pharm. Bull. 22(2):224-226.
`Rubin et a1, “Principles ofCancer Treatment-1”, 12 ONCO IV 1, May
`2003.
`Wilen et al., 1977, Tetrahedron 33:2725.
`Wilen. 1972, lab/es ofResolving Agents and Optical Resolutions,
`EL. Elicl, cd., Univ. ofNotrc Damc Press, Notrc Dame, IN pp. 268.
`Wolff ed., 1995, Burger ’s M’edicinal Chemistry andDrug Discovery.
`5’11 ed.., pp. 172-178, 949-982.
`N. Ake Jonnson, 1972. “Chemical Structure and Teratogenic Prop—
`erties,” Acta Pharm.. pp. 521-542.
`thalidomide,
`Alexanian
`et
`al.,
`2004,
`“VTD (Velcade,
`dexamethasone) as primary therapy for newly-diagnosed multiple
`myeloma.” Ant. Soc. Hematol. 46th Ann. Meeting Dec. 4-7, 2004,
`San Diego, CA Abstract #210.
`Anderson, 2000, “Thalidomide: Therapeutic potential in hemato-
`logic malignancies,” Seminars in Hematology 37(1 Supp 3): 1-4.
`Attal et al., 2004, “Maintenance treatment with thalidomide after
`autologous transplantation for myeloma: First analysis of a pro spec-
`tive randomized study of the Intergroupe Francophone du Myelome
`(1PM 99 02),” Am. Soc. Hematol. 46th Ann. Meeting Dec. 4-7, 2004,
`San Diego, CA Abstract #535.
`Bernardeschi et al., 2003. J. Exp. Clin. Cancer Res. 22(4):129—133.
`Corral et al., 1999, “Differential cytokine modulation and T cell
`activation by two distinct classes of thalidomide analogues that are
`potent inhibitors of'l'NP-alpha.” J. Immunol. 163(1):380-386.
`Davies et al., 2001. “Thalidomide and immunomodulatory deriva-
`tives augment natural killer cell cytotoxicity in multiple myeloma,”
`Blood 98(1):210-216.
`Dimopoulos et al ., 2004, “Primary treatment with puilsed melphalan,
`dexamethasone, thalidomide (MDT) for symptomatic patients with
`multiple myeloma 3775 years of age,” Am. Soc. Hematol. 46th Ann.
`Meeting Dec. 4—7. 2004, San Diego, CA Abstract #1482.
`Eisen et al., 2000, “Continuous low dose Thalidomide: a phase II
`study in advanced melanoma, renal cell, ovarian and breast cancer,"
`Br. J. Cancer 82(4):812-8l7.
`Fakhouri et al., 2004, “Thalidomide in patients with multiple
`myeloma and renal failure,” Br. J. Haematol. 125:90-102.
`Fenk et al.. 2005. “Single-agent thalidomide for treatment of first
`relapse following high-dose chemotherapy in patients with multiple
`myeloma.” Leukemia 19(1):156-159.
`Gupta et al., 2001. “Adherence of multiple myeloma cells to bone
`marrow stromal cells upregulates vascular endothelial growth factor
`secretion: therapeutic applications.” Leukemia 15(12):l950-1961.
`
`Apotex EX. 1001, p. 2
`
`Apotex Ex. 1001, p. 2
`
`

`

`US 8,741,929 B2
`Page 3
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`
`Haslett et al., 2003, “Thalidomide and a thalidomide analogue drug
`costimulate Virus-specific CD8+ T cells in vitro,” J. Infect. Dis.
`187(6):946-955.
`Hideshima et al., 2000, “Thalidomide and its analogs overcome drug
`resistance of human multiple myeloma cells to conventional
`therapy,” Blood 96(9):2943-2950.
`Offidani et al., 2003, Thalidomide plus oral melphalan for advanced
`multiple myeloma:
`a phase II
`study. Haematologica. Dec.
`2003;88(12):1432-1433.
`Palumbo et al., 2004, “A prospective randomized trial of oral
`melphalan prednisone.
`thalidomide (MPT) vs. oral mclphalan,
`prcdnisonc (MP): An interim analysis,” Am. Soc. Hematol. 46th Ann.
`Meeting Dec. 4-7, 2004, San Diego, CA Abstract #207.
`Raje et al., 1999, “Thalidomideia revival story,” N. Engl. J Med.
`341(21):1606-1609.
`Rajkumar et al., 2004, “Thalidomide plus dexamethasone versus
`dexamethasone alone in newly diagnosed multiple myeloma
`(E1A00): Results of a phase III trial coordinated by the Eastern
`Cooperative Oncology Group,”Am. Soc. Hematol. 46th Ann. Meet-
`ing Dec. 4-7, 2004. San Diego. CA Abstract #205.
`Rajkumar et al., 2000,
`“Prognostic value of bone marrow
`angiogenesis in multiple myeloma.” Clin. Cancer Res. 6(8):3111-
`3 116.
`Ribatti et al., 1999, “Bone marrow angiogenesis and mast cell density
`increase simultaneously with progression of human multiple
`myeloma,” Br. J. Cancer 79(3-4):451-455.
`Singhal et al., 1999, Antitumor activity of thalidomide in refractory
`multiple myeloma, N. Engl. J. Med. 341(21): 1565-1571.
`Steins et al , 2002, “Efficacy and safety of thalidomide in patients
`with acute myeloid leukemia," Blood 99(3):834-839.
`Vacca et al., 1999, “Bone marrow neovascularization, plasma cell
`angiogenic potential. and matrix metalloproteinase-2 secretion par-
`allel progression of human multiple myeloma,” Blood 93(9):3064-
`3073.
`Wohrer et al.. 2004, “Effective treatment of primary plasma cell
`leukemia with thalidomide and dexamethasoneia case report,”
`Hematol. J. 5(4):361-363.
`Bach, 1963, “Thalidomide in Cancer Chemotherapy,” The Lancet,
`No 1271, p. 71.
`Bach, 1963, “Studies on the Possible Anti-Neoplastic Effect of
`Thalidomide,” Acta Pathologica F.t Microbiologica Scandinavica
`59:491-499.
`Chaundhry, 1966, Cancer Research, “Effect of Prednisolone and
`Thalidomide on Induced Submandibular Gland Tumors in Hamster,”
`26(part 1)1884-86.
`DiPaolo, 1963, “Effect ofThalidomide on aVariety ofTransplantahle
`Tumors," Cancer Chemotherapy Reports No. 29, p. 99-102.
`DiPaolo, 1963, “In vitro Test Systems for Cancer Chemotherapy, II.
`Correlation of in vitro Inhibition of Dehydrogenase and Growth with
`in vivo Inhibition of Ehrlich Asoites Tumor,” Proceedings of the
`Society for Experimental Biology & Medicine, 114:384-387.
`DiPaolo, 1964, “Thalidomide: Effects on Ehrlich Ascites Tumor
`Cells in vitro” Science 144: 1583.
`Mauad, 1963, “Clinical Improvements Obtained in Advanced Caner
`Patients with Treatment with Thalidomide Associated with Hor-
`mones,” Anais Paulistas de Medicina c Cirurgia 86:13-40.
`Roe and Mitchley, 1963, “Thalidomide and Neoplasia” Nature
`200:1016-1017.
`Liu et al., “Phase 1 study of CC-5013 (Revimid), a thalidomide
`derivative. in patients with refractory metastatic cancer,” American
`Society ofClinical Oncology, Abstract #927, 2003.
`Zangari et al., “Results ofphase 1 study ofCC-5013 for the treatment
`of multiple myeloma (MM) patients who relapse after high dose
`chemotherapy (IIDCT),” American Society of Hematology, Abstract
`#3226, 2001.
`7.eldis et al., “Update on the evolution ofthe IMiDTM,” International
`Society for Biological Therapy of Cancer, Oral Abstract. 2003.
`Anderson. “Moving disease biology from the laboratory to the
`clinic,” Seminars in Oncology, 2002 29:17-20.
`
`Barlogie et al., “Total Therapy II (TTII) for newly diagnosed multiple
`myeloma (MM): preliminary data on feasibility and efficacy in the
`first 231 enrolled patients; comparison with predecessor trial total
`therapyI ((TTI) (N:231)," Blood, Abstract # 2857. Dec. 7-11, 2001,
`American Society of Hematology.
`Barlogie et al., “High-dose therapy immunomodulatory drugs in
`multiple myeloma,” Seminars in Oncology, 2002, 29 (6):26-33.
`Barlogie et al., “Introduction: Thalidomide and the IMiDs in multiple
`myeloma." Seminars in Hematology, 2003, 40 (4)11-2.
`Barlogie, “Thalidomide and CC-5013 in Multiple Myeloma: The
`University of Arkansas experience,” Seminars in Hematology, 2003,
`40 (4):33-38.
`Bartlett et al., “The evolution ofthalidomide and its IMiD derivatives
`as anticancer agents,” Nature Reviews Cancer. 2004, 4 (4): 1-9.
`Bartlett et al., “PhaseI study to determine the safety, tolerability and
`immunostimulatory activity of thalidomide analogue CC-5013 in
`patients with metastatic malignant melanoma and other advanced
`cancers,” British Journal of Cancer, 2004, 90:955-961.
`Battegay, “Angiogenesis: mechanistic insights, ncovascular diseases,
`and therapeutic prospects,” J. Mol. Med., 1995, 73:333-346.
`Baz et
`al.,
`“Doxil
`(D). vincristine (V),
`reduced frequency
`dexamethasone (d) and revlimid (R) ('DVd-R) results in a high
`response rate in patients with refractory multiple myeloma (RMM),7’
`Blood. Abstract 77‘ 2559, American Society of Hematology, Dec.
`10-13, 2005.
`Brennen et al., “Thalidomide and analogues: current proposed
`mechanisms and therapeutic usage,” Clinical Prostate Cancer, 2004,
`3 (1):.54-61.
`Ce gene Corporation, “Celgene advances immunomodulatory drug
`(IMiDTM) clinical progranl,” Press Release, Feb. 2000.
`Ce gene Corporation. “Initial Phase I solid tumor data on Celgene’s
`lead IMiDTM, RevimidTM.” Press Release, Jun. 2001.
`Ce gene Corporation, “Celgene Corporation receives orphan drug
`designation for RevimidTM for multiple myeloma,” Press Release,
`Oct. 2001.
`Ce gene Corporation, “Celgene Corporation announces third quarter
`results. Thalomid® (thalidomide) sales increase 24%. Prescriptions
`up 50%. Enhanced S.'1'.E.l’.S.® launched. Pilot d-MI‘H data pre-
`sented,” Press Release, Oct. 2001.
`Ce gene Corporation, “Celgene expands clinical development pro—
`gram for RevimidTM. Five additional trials of Revimid initiated in
`hematological and solid tumor cancers," Press Release, Jun. 2002.
`Ce gene Corporation, “Celgene Corporation announces third quarter
`results. Thalomid® (thalidomide) revenue increases 41% to $30.5
`mi lion. Pivotal programs for Thalomid and RevimidTM finalized.
`Peer-reviewed publications ofThalomid and Revimid data. First J,\IK
`inhibitor advanced to Phase I clinical trial." Press Release, Oct. 2002.
`Ce gene Corporation, “Blood reports Revimid1M has anti -tumor
`activity in patients with relapsed and refractory multiple myeloma,”
`Press Release, Nov. 1, 2002.
`Ce gene Corporation, “Celgene provides update on clinical pipeline.
`Ce gene Announces first target indication for ActimidTM. CC-8490.
`SelCID1M program to advance based on results from Phase I/II trial of
`CC-1088. First JNK inhibitor successfully completes phase I trial,”
`Press Release, Jan. 2003.
`Ce gene Corporation. “Celgene Corporation announces fourth quar-
`ter and full year results for 2002,” Press Release. Jan. 2003.
`Ce gene Corporation. “Celgene receives fast track status from FDA
`for RevimidTM in multiple myloma.” Press Release, Feb. 2003.
`Ce gene Corporation. “Celgene receives fast track status from FDA
`for RevimidTM in myelodysplastic sydrornes,” Press Release, Apr.
`2003.
`Ce gene Corporation, “New Revimid1M clinical data shows potential
`as novel approach to treating myelodysplastic syndromes (MDS),”
`Press Release, May 2003.
`Ce gene Corporation. “Celgenc corporation reports strong operating
`performance in second quarter as total sales increase 100 percent and
`profits rise,” Press Release, Jul. 2003.
`Ce gene Corporation, “Celgene corporation reports record operating
`performance in third quarter as total revenue increases 117% and
`profits rise,” Press Release, Oct. 2003.
`
`
`
`Apotex EX. 1001, p. 3
`
`Apotex Ex. 1001, p. 3
`
`

`

`US 8,741,929 B2
`
`Page 4
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`
`Celgene Corporation, “Celgene corporation advances ActimidTM
`(CC-4047) into phase II trial for prostate cancer,” Press Release, Oct.
`2003.
`“Additional clinical dam presented on
`Celgene Corporation,
`RevimidTM in myelodysplastic sydromes at the American Society of
`Hematology 45th annual meeting,” Press Release, Dec. 2003.
`Celgene Corporation, “Celgene corporation reviews 2003 achieve-
`ments and announces 2004 financial outlook,” Press Release, Jan.
`2004.
`Celgene Corporation, “RevlimidTM receives orphan drug designation
`from the European commission for multiple myeloma,” Press
`Release, Feb. 2004.
`Celgene Corporation, “RevlimidTM receives orphan drug designation
`from the European connnission for myelodysplastic sydromes.”
`Press Release, Mar. 2004.
`Celgene Corporation, “Celgene corporation reports record operating
`performance in first quarter with strong revenue growth and profits.”
`Press Release, Apr. 2004.
`Celgene Corporation, “Celgene announces plans to stop phase III
`trials in melanoma due to lack of efficacy," Press Release. Apr. 2004.
`Dalgleish, et al., “New thalidomide analogues; anti-cancer, anti-
`angiogenic and immunostimulatory,” British Journal of Cancer,
`2001, 85 (1)25.
`Dalgleish et al., “Thalidomide analogues CC-5013 and CC-4047
`induce T cell activation and IL-12 production in patients with both
`solidtumours and relapsed and refractory multiple myeloma,” British
`Journal of Cancer, 2003, 88(‘Suppl 1), $25-$54.
`Database Pharmaml XP002369094 retrieved from STN. Database
`accession No. 1659300, & Marketletter, Oct. 9, 2001.
`Database NLDB XP002369095 retrieved from STN. Database acces-
`sion No. 2002135280, & Marketletter, Jun. 18, 2001.
`Davies et al., “Thalidomide (Thal) and immunomodulatory deriva-
`tives (IMiDs) augment natural killer (NK) cell cytotoxicity in mul-
`tiple myeloma(MM)),” Abstract # 3617, American Society of Hema-
`tology. Dec. 1-5. 2000.
`and immunomodulatory
`(Thal)
`Davies
`et
`al.,
`“Thalidomide
`derivatives (IMiDs) augment natural killer (NK) cell cytotoxicity in
`multiple myeloma ~MM),” Abstract # P222, VIIIth International
`Myeloma Workshop, May 4-8, 2001.
`Dibbs et al.. “Thalidomide and thalidomide analogs suppress TNFy
`secretion by myocytes,” Abstract # 1284, Circulation, 1998.
`Dimopoulos et al., “Results of thalidomide and IMIDs in multiple
`myeloma,”, Abstract # P121 .4, International Multiple Myeloma
`\Vorkshop, May 23-27, 2003.
`Dimopoulos et al.. "Treatment of plasma cell dyscrasias with
`thalidomide and its derivatives,” Journal of Clinical Oncology, Dec.
`1,2003, 21 (23)4444-4454.
`Dimopoulos et al., “Study of lenalidomide plus dcxamethasone ver-
`sus dexamethasone alone in relapsed or refractory multiple myeloma
`(MM): Results of a phase 3 Study (MM-010).”. Abstract # 6. Ameri-
`can Society ofIIematology, Dec. 10-13. 2005.
`Dredge et al., A costimulatory thalidomide analog enhances the par-
`tial anti-tumor immunity of an autologous vaccination in a model of
`colorectal cancer, Abstract # 491. American Association for Cancer
`Research. Apr. 6—10. 2002.
`Dredge et al ., “Adjuvants and the promotion of Th 1 -type cytokines in
`tumour immunotherapy,” Cancer Immunol.
`Immunother., 2002,
`5 1: 521-53 1.
`Dredge et al., “Immunological effects of thalidomide and its chemi-
`cal and functional analogs.” Critical Reviews in Immunology. 2002.
`22 (5&6):425-437.
`immunity induced by a
`Dredge et al., “Protective antitumor
`costimulatory thalidomide analog in conjunction with whole tumor
`cell vaccination is mediated by increased Th1 -type immunityl ,” The
`Journal of Immunology. 2002. 168:4914-4919.
`Dredge et al.. “Recent developments in antiangiogenic therapy.”
`Expert Opin. Biol. Ther, 2002, 2 (8):953-966.
`Dredge et al., “Angiogenesis inhibitors in cancer therapy," Current
`Opinion in Investigational Drugs. 2003, 4 (6):667-674.
`
`Dredge et al.. “Thalidomide analogs as emerging anti-cancer dm gs,”
`Anti-Cancer Drugs. 2003. 14:331—335.
`Fickentscher et al., “Stereochemical properties and teratogenic activ-
`ity of some tetrahydrophthalimides,” Molecular Pharmacology,
`1976,131133-141.
`Figg et al., “lnhibiti on ofangiogenesis: treatment options for patients
`with metastatic prostate cancer.” Investigational New Drugs. 2002.
`20(2):183-194.
`Galustian et al., “Thalidomide-derived immunomodulatory drugs as
`therapeutic agents,” Expert Opin. Biol. Ther, 2004, 4 (12): 1-8.
`Glaspy et al., “The potential role of thalidomide and thalidomide
`analogs in melanoma," Clinical Advances in Hematology & Oncol—
`ogy, 2004, 1-7.
`Goy, “Mantle Cell Lymphoma: Evolving Novel Options.” Current
`Oncology Reports, 2007, 9(5):391-398.
`Gupta et al., “Adherence of multiple myeloma cells to bone marrow
`stromal cells upregulates vascular endothelial growth factor secre—
`tion: therapeutic applications,” Leukemia, 2001, 15:1950-1961.
`Hayashi et al., “Mechanisms whereby immunomodulatory analogs
`of thalidomide augment autologous NK cell anti-myeloma immu-
`nity,” Blood, Abstract #3219, Dec. 6-10, 2002, American Society of
`Hematology.
`IIe, W., et al., 1993, Abstract of papers, 206th American Chemical
`Society. Chicago. IL; Med. Chem.. paper 216.
`Helm et al.. “Comparative teratological investigation of compounds
`of structurally and pharmacologically related to thalidomide,”
`Arzneimittel ForschungDrug Research, 1981, 31 (1)941-949.
`IIernandeZ-Illizaliturr et al ., “Addition of immunomodulatory drugs
`CC5013 or CC4047 to rituximab enhances anti-tumor activity in a
`severe combined immunodeficiency (SCID) mouse lymphoma
`model,” Abstract # 235, American Society of Hematology, Dec. 6-9,
`2003.
`1r ernandez-Ilizaliturri, et al., “Immunomodulatory Drug CC-5013 or
`CC-4047 and Rituximab Enhance Antitumor Activity in a Severe
`Combined Immunodeficient Mouse Lymphoma Model,” Clinical
`Cancer Research. 11(16):5984-5992. 2005.
`P ideshima et al., “Thalidomide and its analogs overcome drug
`rcsistancc of human multiple myeloma cells to conventional
`therapy,” Blood, 2000, 96:2943-2950, American Society of Hema-
`tology.
`P ideshima et al., “Thalidomide (Thal) and its analogs overcome dmg
`resistance of human multiple myeloma (MM) cells to conventional
`therapy,” Abstract 1313, American Society of Hematology. Dec. 1-5,
`2000.
`P unt et al.. “Markers of endothelial and haemostatic activation in the
`use of CC-4047, a stmctural analogue of thalidamicle, in relapsed
`myeloma." Blood, Abstract # 3216. Dec. 6-10. 2002, American Soci—
`ey of Hematology.
`P ussein et al.. “Doxil (D), vincristine (V), reduced frequency
`dexamethasone ((1) and Revlimid (DVd—R) a phase I/II trial
`in
`advanced relapsed/refractmy multiple myeloma (Rmm) patients,”
`Blood, Abstract #208, American Society of Hematology, Dec. 4-7,
`2 04.
`P wu et al.. “Thalidomide and its analogues in the treatment ofmeta-
`static melanoma,” Chemotherapy Foundation Symposium, Abstract
`#44, 2002.
`Kyle, “Current therapy of multiple myeloma," Internal Medicine,
`2 02, 41 (3)175-180.
`Kyle et al., “Multiple myeloma.” New England Journal of Medicine,
`2004, 351:1860-1873.
`Leblanc et a1 , “Innnunomodulatory drug co stimulates T cells Via the
`B7—CD28 pathway." Blood, 2004, 103: 1787-1790, American Society
`of Hematology.
`Lentzsch et al., “In vivo activity ofthalidomide and immunomodula-
`tory drugs against multiple myeloma,”VIIIth International Myeloma
`Workshop, Abstract #P225, May 4-8. 2001.
`Lentzsch et al., “Immunomodulatory derivative of thalidomide
`(.lMiD CC-4047)
`determine
`the
`lineage
`commitment
`of
`hematopoietic progenitors by down regulation ofGATA-l and modu-
`lation of cytokine secretion,” Abstract # 3073, American Society of
`Hematology, Dec. 6-9, 2003
`
`
`
`Apotex EX. 1001, p. 4
`
`Apotex Ex. 1001, p. 4
`
`

`

`US 8,741,929 B2
`Page 5
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`
`Lentzsch et a1., “Immunomodulatory derivative of thalidomide
`(IMiD CC-4047) down regulates CAAT/enhancer-binding protein
`y(C/'EBP y) in multiple myeloma (MM),” Abstract # 3456, American
`Society ofHematology, Dec. 6-9, 2003.
`Luzzio et al.. “Thalidomide analogues: derivatives of an orphan drug
`with diverse biological activity,” Expert Opin. Ther. Patents, 2004, 14
`(2):215-229.
`analogues.”
`thalidomide
`“y-Fluoro-substituted
`Man
`et
`a1.,
`Bioorganic & Medicinal Chemistry Letters 13, 2003, 3415-3417.
`Marriott et a1., “Immunotherapeutic and antitumour potential of
`thalidomide analogues,” Expert Opin. Biol. Ther., 2001,
`l (4):l-8.
`Marriott et al., “New thalidomide analogues; anti-cancer, anti-
`angiogenic and immunostimulatory,” British Journal of Cancer,
`85:25, Jul. 6, 2001.
`Marriott et a1., “Thalidomide and its analogues have distinct and
`opposing effects on TNP-y andTNFR2 during co-stimulation ofboth
`CD4+ and CD8+ T cells,” Clin. Exp. Immunol, 2002, 130:75-84.
`Marriott et al., “A novel subclass ofthalidomide analogue with anti-
`solid tumor activity in which caspase-dependent apoptosis is associ-
`ated with altered expression of bc1-2 family proteinsl." Cancer
`Research, 2003, 63:593-599.
`Marriott et a1., “Thalidomide derived immunomodulatory drugs
`(IMiDs) as potential therapeutic agents,” Current Drug Targetsi
`Immune, Endocrine & Metabolic Disorders, 2003, 3:181-186.
`Masellis et al.. “Changes in gene expression in bone marrow
`mesenchymal progenitor cells as a consequence of IMiD therapy in
`multiple myeloma patients,” Blood, Abstract # 1548, Dec. 7-11,
`2001, American Society of Hematology.
`McCarty, “Thalidomide may impede cell migration in primates by
`down-regulating integrin y-chains: potential therapeutic utility in
`solid malignancies, proliferative retinopathy, inflammatory disor-
`ders, neointimal hyperplasia, and osteoporosis,” Medical Hypoth-
`eses,1997,49:123-131.
`Mitsiades et al , “Apoptic signaling induced by immtmomodulatory
`thalidomide analogs (Imids) in human multiple myeloma cells: thera-
`peutic implications,” Abstract # 3224, Dec. 7-1 1, 2001, American
`Society of Hematology.
`Mitsiades et al, “Apoptic signaling induced by immunomodulatory
`thalidomide analogs in human multiple rnyelorrra cells: therapeutic
`implications.” Blood, 2002. 99:4525—4530. American Society of
`Hematology.
`Mitsiades et a1., “CC-5013 Celgene,” Current Opinion in Investiga-
`tional Drugs, 2004, 5 (6):635-647.
`Moutouh et a1., “Novel immunomodulatory drugs (IMiDs®): A
`potential. new therapy for y-hemoglobinopathies.” Abstract it 3740.
`American Society of Hematology, Dec. 4-7, 2004.
`Patten et al., “The early use of the serum free light chain assay in
`patients with relapsed refractory myeloma receiving treatment with a
`thalidomide analogue (CC-4047),” Abstract # 1640, American Soci-
`ety of Hematology. Dec. 6-9. 2003.
`Payvandi et al.. “Effects ofa thalidomide analog on binding activity
`of transcription factors and cell cycle progression of multiple
`myeloma cell lines." Blood, Abstract #2487, Dec. 1-5, 2000, Ameri-
`can Society of Hematology.
`Payvandi et al.. “The thalidomide analogs IMiDs enhance expression
`ofCD69 stimulatory receptoron natural killercells,” Abstract # 1793,
`American Association for Cancer Research, Mar. 24-28, 2001.
`Payvandi et a1., “Thaliomide analogs IMiDs inhibit expression of
`cyclooxygenase-2 in multiple myeloma cell line and LPS stimulated
`PBMC s.” Blood. Abstract # 2689. Dec. 7-1 1 . 200 1 . American Society
`ofHematology.
`Payvandi et a1., “Thalidomide and IMiDS inhibit microvessel forma-
`tion from human arterial rings in the absence of human liver
`microsomes,” Blood, Abstract 4 5046, Dec. 6-10, 2002, American
`Society of Hematology.
`Payvandi et al., “CC-5013 inhibits the expression of adhesion mol-
`ecules ICAM-1 and CD44 and prevents metastasis ofB1 6 F 10 mouse
`melanoma cells in an animal model," American Society of Clinical
`Oncology. Abstract # 992, 2003.
`
`Payvandi et a1., “Irmnunomodulatory drugs inhibit expression of
`cyclooxygenase-2 from TNF-y. IL-1y, and LPS—stimulated human
`PBMC in a partially IL-lO-dependent manner,” Cellular Immunol-
`ogy, 2004, 81-88.
`Raje et a1., “Combination of the mTOR inhibitor raparnycin and
`CC-5013 has synergistic activity in multiple myeloma,” Blood, Dec.
`15. 2004. 104 (13)4188-4193.
`Rajkumar et al.. “Combination therapy with lenalidonride plus
`dexamethasone (Rcv/Dex) for newly diagnosed myeloma,” Blood,
`Dec. 15, 2005, 106 (13)4050-4053.
`an
`study of oral CC5013,
`Richardson et al.,
`“A Phase
`1
`immunomodulatory thalidomide (Thal) derivative, in patients with
`relapsed and refractory multiple myeloma (341%),” Blood, Abstract
`#3225, Dec. 7-11, 2001, American Society ofHematology.
`Richardson et a1., “Immunomodulatory drug CC-5013 overcomes
`drug resistance and is well tolerated in patients with relapsed multiple
`myeloma." Blood, 2002 100:3063-3067. American Society ofHema—
`tology.
`Richardson et al., “A multi-center, randomized, phase 2 study to
`evaluate the efficacy and safety of2 CDC-5013 dose regimens when
`used alone or in combination with dexamethasone (Dex) for the
`treatment ofrelapsed or refractory multiple myeloma (MM) ,” Blood,
`Abstract #825, American Society of Hematology, Dec. 6-9, 2003.
`Richardson et a1., “Immunomodulatory analogs of thalidomide: an
`emerging new therapy in myeloma,” Journal of Clinical Oncology,
`2004, 22(16) 3212-3214.
`Richardson et al., “A multicenter, single-arm, open-label study to
`evaluate the efficacy and safety of single-agent lenalidomide in
`patients with relapsed and refractory multiple myeloma; preliminary
`results,” IOth International Myeloma Workshop, Apr